beraprost sodium : The organic sodium salt of beraprost. It is used in the treatment of chronic arterial occlusive disease and primary pulmonary hypertension in Japan. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 23663404 |
| CHEMBL ID | 435883 |
| CHEBI ID | 31270 |
| SCHEMBL ID | 22096 |
| MeSH ID | M0322690 |
| Synonym |
|---|
| dorner |
| procylin |
| ym-533 |
| berasus la |
| beraprost sodium |
| careload |
| ml-1129 |
| trk-100 |
| ru-55100 |
| trk-100stp |
| trk 100 |
| ml 1129 |
| beraprost sodium salt |
| beraprost sodium [usan] |
| mdl 201129 |
| 1h-cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-, monosodium salt |
| sodium (+-)-(1r,2r,3as,8bs)-2,3,3a,8b-tetrahydro-2-hydroxy-1-((e)-(3s,4rs)-3-hydroxy-4-methyl-1-octen-6-ynyl)-1h-cyclopenta(b)benzofuran-5-butyrate |
| 88475-69-8 |
| CHEMBL435883 |
| mdl-201129 |
| NCGC00183097-01 |
| unii-15k99vdu5f |
| beraprost sodium [usan:jan] |
| 15k99vdu5f , |
| cas-88475-69-8 |
| tox21_112914 |
| dtxsid2048585 , |
| dtxcid2028511 |
| beraprost sodium salt [mi] |
| beraprost sodium [mart.] |
| gp-1681 |
| beraprost sodium [jan] |
| sodium (+/-)-(1r,2r,3as,8bs)-2,3,3a,8b-tetrahydro-2-hydroxy-1-((e)-(3s,4rs)-3-hydroxy-4-methyl-1-octen-6-ynyl)-1h-cyclopenta(b)benzofuran-5-butyrate |
| 2,3,3a,8b-tetrahydro-2-hydroxy-1((e)-(3s)-3-hydroxy-4-methyl-1-octen-6-ynyl)-1h-cyclopenta(b)benzofuran-5-butyric acid sodium salt |
| beraprost sodium [who-dd] |
| DB05229 |
| SCHEMBL22096 |
| sodium 4-((2r,3as,8bs)-2-hydroxy-1-((3s,e)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)-2,3,3a,8b-tetrahydro-1h-cyclopenta[b]benzofuran-5-y l)butanoate |
| J-524272 |
| 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-yn-1-yl)-1h-cyclopenta[b]benzofuran-5-butanoic acid sodium salt |
| 1290611-29-8 |
| AKOS027470142 |
| beraprost na |
| berasil |
| CHEBI:31270 |
| berast |
| beracle |
| sodium 4-{(1r,2r,3as,8bs)-2-hydroxy-1-[(1e,3s)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-2,3,3a,8b-tetrahydro-1h-benzo[b]cyclopenta[d]furan-5-yl}butanoate |
| careload la |
| berastolin |
| prorner |
| AKOS032949706 |
| Q27888026 |
| EX-A4022 |
| sodium;4-[(1r,2r,3as,8bs)-2-hydroxy-1-[(e,3s)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1h-cyclopenta[b][1]benzofuran-5-yl]butanoate |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Role | Description |
|---|---|
| antihypertensive agent | Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism. |
| platelet aggregation inhibitor | A drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. |
| prostaglandin receptor agonist | An agonist that binds to and activates prostaglandin receptors. |
| vasodilator agent | A drug used to cause dilation of the blood vessels. |
| anti-inflammatory agent | Any compound that has anti-inflammatory effects. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| organic sodium salt | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| AR protein | Homo sapiens (human) | Potency | 8.3058 | 0.0002 | 21.2231 | 8,912.5098 | AID743035; AID743036; AID743063 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 6.0070 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 10.8360 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743078; AID743079; AID743080; AID743091 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 39.8107 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| virion membrane | Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID247894 | Inhibition of ADP (5 uM) induced platelet aggregation in human platelet rich plasma | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | Development of dual-acting benzofurans for thromboxane A2 receptor antagonist and prostacyclin receptor agonist: synthesis, structure-activity relationship, and evaluation of benzofuran derivatives. |
| AID301228 | Inhibition of ADP-induced platelet aggregation in human platelet rich plasma | 2007 | Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21 | Structure-activity studies on diphenylpyrazine derivatives: a novel class of prostacyclin receptor agonists. |
| AID247957 | Inhibition of U-46,619 (4 uM) induced platelet aggregation in human platelet rich plasma | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | Development of dual-acting benzofurans for thromboxane A2 receptor antagonist and prostacyclin receptor agonist: synthesis, structure-activity relationship, and evaluation of benzofuran derivatives. |
| AID302640 | Inhibition of ADP-induced platelet aggregation in human platelet rich plasma | 2007 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23 | Structure-activity relationship study on the 6-membered heteroaromatic ring system of diphenylpyrazine-type prostacyclin receptor agonists. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (54.85) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||